|View printer-friendly version|
|December 05, 2002 4:28 p.m.|
|Teva Announces Approval of Amoxicillin for Oral Suspension|
Jerusalem, Israel, December 5, 2002 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has approved the company's ANDA for Amoxicillin for Oral Suspension (BID), 200 mg/5 mL and 400 mg/5 mL. A launch date will be determined soon.